During the last session, Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares were 0.88 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $4.94, reflecting an intraday gain of 0.61% or $0.03. The 52-week high for the ADPT share is $5.80, that puts it down -17.41 from that peak though still a striking 53.85% gain since the share price plummeted to a 52-week low of $2.28. The company’s market capitalization is $728.50M, and the average intraday trading volume over the past 10 days was 1.13 million shares, and the average trade volume was 1.24 million shares over the past three months.
Adaptive Biotechnologies Corp (ADPT) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.50. ADPT has a Sell rating from 1 analyst(s) out of 11 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Adaptive Biotechnologies Corp (ADPT) registered a 0.61% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.61% in intraday trading to $4.94, hitting a weekly high. The stock’s 5-day price performance is -10.51%, and it has moved by 14.88% in 30 days. Based on these gigs, the overall price performance for the year is 3.78%. The short interest in Adaptive Biotechnologies Corp (NASDAQ:ADPT) is 9.91 million shares and it means that shorts have 9.16 day(s) to cover.
The consensus price target of analysts on Wall Street is $14, which implies an increase of 64.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $18 respectively. As a result, ADPT is trading at a discount of -264.37% off the target high and -1.21% off the low.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
Statistics show that Adaptive Biotechnologies Corp has underperformed its competitors in share price, compared to the industry in which it operates. Adaptive Biotechnologies Corp (ADPT) shares have gone up 64.12% during the last six months, with a year-to-date growth rate less than the industry average at 10.87% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 17.10% this quarter and then jump 39.60% in the quarter after that. In the rating firms’ projections, revenue will increase 1.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 40.31M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 47.07M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -32.91%. While earnings are projected to return 21.47% in 2024, the next five years will return 21.60% per annum.
ADPT Dividends
Adaptive Biotechnologies Corp is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Adaptive Biotechnologies Corp insiders own 1.92% of total outstanding shares while institutional holders control 98.54%, with the float percentage being 100.47%. VIKING GLOBAL INVESTORS LP is the largest shareholder of the company, while 241.0 institutions own stock in it. As of 2024-06-30, the company held over 29.99 million shares (or 20.5736% of all shares), a total value of $108.58 million in shares.
The next largest institutional holding, with 14.0 million shares, is of RUBRIC CAPITAL MANAGEMENT LP’s that is approximately 9.603% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $50.68 million.
